Related Experiment Video
Updated: Jun 1, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and
Jeffrey M Schafer1, Diane E Peters, Thomas Morley
1Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Although considerable progress has been made in elucidating the etiology of the disease, the prognosis for individuals diagnosed with HNSCC remains poor, underscoring the need for development of additional treatment modalities. HNSCC is characterized by the upregulation of a large number of proteolytic enzymes, including urokinase plasminogen activator (uPA) and an assortment of matrix metalloproteinases (MMPs) that may be expressed by tumor cells, by tumor-supporting stromal cells or by both. Here we explored the use of an intercomplementing anthrax toxin that requires combined cell surface uPA and MMP activities for cellular intoxication and specifically targets the ERK/MAPK pathway for the treatment of HNSCC. We found that this toxin displayed strong systemic anti-tumor activity towards a variety of xenografted human HNSCC cell lines by inducing apoptotic and necrotic tumor cell death, and by impairing tumor cell proliferation and angiogenesis. Interestingly, the human HNSCC cell lines were insensitive to the intercomplementing toxin when cultured ex vivo, suggesting that either the toxin targets the tumor-supporting stromal cell compartment or that the tumor cell requirement for ERK/MAPK signaling differs in vivo and ex vivo. This intercomplementing toxin warrants further investigation as an anti-HNSCC agent.
Insights
A novel intercomplementing anthrax toxin shows promise for treating head and neck squamous cell carcinoma (HNSCC). This toxin targets the ERK/MAPK pathway, demonstrating significant anti-tumor effects in vivo by inducing cell death and inhibiting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer with a poor prognosis, necessitating novel therapeutic strategies.
- HNSCC is characterized by elevated levels of proteolytic enzymes like urokinase plasminogen activator (uPA) and matrix metalloproteinases (MMPs).
Purpose of the Study:
- To investigate the therapeutic potential of an intercomplementing anthrax toxin targeting the ERK/MAPK pathway for HNSCC treatment.
- To evaluate the systemic anti-tumor activity and mechanism of action of this novel toxin against HNSCC xenografts.
Main Methods:
- Utilized an intercomplementing anthrax toxin requiring cell surface uPA and MMP activity for intoxication.
- Administered the toxin to xenografted human HNSCC models to assess anti-tumor efficacy.
- Analyzed tumor cell death (apoptosis, necrosis), proliferation, and angiogenesis.
Main Results:
- The intercomplementing toxin exhibited significant systemic anti-tumor activity in HNSCC xenografts.
- Observed induction of apoptotic and necrotic tumor cell death, reduced tumor cell proliferation, and impaired angiogenesis.
- HNSCC cell lines were insensitive to the toxin ex vivo, suggesting a potential role for the tumor-supporting stromal compartment or in vivo-specific signaling differences.
Conclusions:
- The intercomplementing anthrax toxin demonstrates potent in vivo anti-HNSCC efficacy.
- The toxin's mechanism may involve targeting stromal cells or differential in vivo/ex vivo ERK/MAPK signaling requirements.
- This toxin represents a promising candidate for further investigation as an anti-HNSCC therapeutic agent.
